Literature DB >> 19621989

Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes.

Nimisha Gandhi1, Zainulabedin Saiyed, Samikkannu Thangavel, Jose Rodriguez, K V K Rao, Madhavan P N Nair.   

Abstract

The existence of multiple subtypes of HIV-1 worldwide has created new challenges to control HIV-1 infection and associated neuropathogenesis. Previous studies indicate a difference in neuropathogenic manifestations of HIV-1-associated neuroAIDS between clade B- and clade C-infected subjects with clade B being more neuropathogenic than clade C. However, the exact mechanism underlying the differences in the neuropathogenesis by both the subtypes remains elusive. Development of neuroAIDS is associated with a complex interplay between proinflammatory and antiinflammatory cytokines and chemokines. In the current study, we hypothesize that HIV-1 clade B and C Tat protein exert differential effects on human primary monocytes leading to differences in gene and protein expression of cytokines implicated in neuroAIDS. Primary human monocytes were treated with clade B and clade C Tat protein and quantitative real time PCR was performed to determine gene expression of proinflammatory cytokines (IL-6 and TNF-alpha) and antiinflammatory cytokines (IL-4 and IL-10). Further, cytokine secretion was measured in culture supernatants by ELISA, whereas intracellular cytokine expression was detected by flow cytometry. Results indicate that monocytes treated with Tat B showed significant upregulation of proinflammatory cytokines, IL-6 and TNF-alpha, as compared to Tat C-treated cultures. However, expression of antiinflammatory molecules and IL-4 and IL-10 was found to be higher in Tat C-treated compared to Tat B-treated cultures. Thus, our result shows for the first time that Tat B and Tat C differentially modulate expression of neuropathogenic molecules that may be correlated with the differences in neuroAIDS manifestation induced by clade-specific infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19621989      PMCID: PMC2853861          DOI: 10.1089/aid.2008.0299

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  34 in total

Review 1.  The influence of cytokines, chemokines and their receptors on HIV-1 replication in monocytes and macrophages.

Authors:  Katherine Kedzierska; Suzanne M Crowe; Stuart Turville; Anthony L Cunningham
Journal:  Rev Med Virol       Date:  2003 Jan-Feb       Impact factor: 6.989

2.  Mechanisms for HIV Tat upregulation of IL-10 and other cytokine expression: kinase signaling and PKR-mediated immune response.

Authors:  James C B Li; Davy C W Lee; Benny K W Cheung; Allan S Y Lau
Journal:  FEBS Lett       Date:  2005-06-06       Impact factor: 4.124

3.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

4.  Proteinuria and endothelial dysfunction in stable HIV-infected patients. A pilot study.

Authors:  Samir K Gupta; Kieren J Mather; Rajiv Agarwal; Chandan K Saha; Robert V Considine; Michael P Dubé
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

Review 5.  The puzzle of HIV-1 subtypes in Africa.

Authors:  W Janssens; A Buvé; J N Nkengasong
Journal:  AIDS       Date:  1997-05       Impact factor: 4.177

6.  The human immunodeficiency virus (HIV) as a newly evolving pathogen.

Authors:  M Essex
Journal:  Southeast Asian J Trop Med Public Health       Date:  1997       Impact factor: 0.267

7.  Neurological manifestations of HIV disease.

Authors:  R S Wadia; S N Pujari; S Kothari; M Udhar; S Kulkarni; S Bhagat; A Nanivadekar
Journal:  J Assoc Physicians India       Date:  2001-03

8.  Methamphetamine enhances HIV-1 infectivity in monocyte derived dendritic cells.

Authors:  Madhavan P N Nair; Zainulabedin M Saiyed; Narayanan Nair; Nimisha H Gandhi; Jose W Rodriguez; Nawal Boukli; Elias Provencio-Vasquez; Robert M Malow; Maria Jose Miguez-Burbano
Journal:  J Neuroimmune Pharmacol       Date:  2008-10-29       Impact factor: 4.147

Review 9.  Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome.

Authors:  Elizabeth Crabb Breen
Journal:  Pharmacol Ther       Date:  2002-09       Impact factor: 12.310

10.  Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease.

Authors:  M I Bukrinsky; H S Nottet; H Schmidtmayerova; L Dubrovsky; C R Flanagan; M E Mullins; S A Lipton; H E Gendelman
Journal:  J Exp Med       Date:  1995-02-01       Impact factor: 14.307

View more
  45 in total

1.  Impact of the HIV Tat C30C31S dicysteine substitution on neuropsychological function in patients with clade C disease.

Authors:  Robert H Paul; John A Joska; Carol Woods; Soraya Seedat; Susan Engelbrecht; Jacqueline Hoare; Jodi Heaps; Victor Valcour; Beau Ances; Laurie M Baker; Lauren E Salminen; Dan J Stein
Journal:  J Neurovirol       Date:  2014-11-01       Impact factor: 2.643

2.  Use of ATP analogs to inhibit HIV-1 transcription.

Authors:  Aarthi Narayanan; Gavin Sampey; Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Jessica Roman; Robert Currer; Hervé Galons; Nassima Oumata; Benoît Joseph; Laurent Meijer; Massimo Caputi; Sergei Nekhai; Fatah Kashanchi
Journal:  Virology       Date:  2012-07-06       Impact factor: 3.616

3.  The Evolving Profile of the Signature Amino Acid Residues in HIV-1 Subtype C Tat.

Authors:  Shambhu Prasad G Aralaguppe; Shilpee Sharma; Malini Menon; Vinayaka R Prasad; Shanmugam Saravanan; Kailapuri G Murugavel; Suniti Solomon; Udaykumar Ranga
Journal:  AIDS Res Hum Retroviruses       Date:  2016-02-09       Impact factor: 2.205

Review 4.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

5.  Human immunodeficiency virus type 1 clade B and C gp120 differentially induce neurotoxin arachidonic acid in human astrocytes: implications for neuroAIDS.

Authors:  Thangavel Samikkannu; Marisela Agudelo; Nimisha Gandhi; Pichili V B Reddy; Zainulabedin M Saiyed; Donald Nwankwo; Madhavan P N Nair
Journal:  J Neurovirol       Date:  2011-04-14       Impact factor: 2.643

6.  Cognitive Function Among Antiretroviral Treatment-Naive Individuals Infected With Human Immunodeficiency Virus Type 1 Subtype G Versus CRF02_AG in Nigeria.

Authors:  Jibreel Jumare; Nicaise Ndembi; Samer S El-Kamary; Laurence Magder; Laura Hungerford; Tricia Burdo; Lindsay M Eyzaguirre; Patrick Dakum; Anya Umlauf; Mariana Cherner; Alash'le Abimiku; Man Charurat; William A Blattner; Walter Royal
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

Review 7.  Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders.

Authors:  William Tyor; Cari Fritz-French; Avindra Nath
Journal:  J Neurovirol       Date:  2013-10-16       Impact factor: 2.643

Review 8.  Genetic variation and function of the HIV-1 Tat protein.

Authors:  Cassandra Spector; Anthony R Mele; Brian Wigdahl; Michael R Nonnemacher
Journal:  Med Microbiol Immunol       Date:  2019-03-05       Impact factor: 3.402

9.  Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: implications for HIV-1-associated neurocognitive disorder.

Authors:  Nimisha Gandhi; Zainulabedin M Saiyed; Jessica Napuri; Thangavel Samikkannu; Pichili V B Reddy; Marisela Agudelo; Pradnya Khatavkar; Shailendra K Saxena; Madhavan P N Nair
Journal:  J Neurovirol       Date:  2010-07       Impact factor: 2.643

10.  Magnetic nanoformulation of azidothymidine 5'-triphosphate for targeted delivery across the blood-brain barrier.

Authors:  Zainulabedin M Saiyed; Nimisha H Gandhi; Madhavan P N Nair
Journal:  Int J Nanomedicine       Date:  2010-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.